Back to Search Results
Image Place holder

Doris Hansen, MD

★★★★★
★★★★★
4.9 (33 ratings)
Specialty: Blood and Marrow Transplant and Cellular Immunotherapy
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Hodgkin Lymphoma, Leukemia, Multiple Myeloma-Plasma Cell Tumor, Non-Hodgkin Lymphoma

Dr. Doris Hansen is an Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Hansen earned her MD from St. George’s University School of Medicine, Grenada. She completed an Internal Medicine Residency and a Hematology/Oncology Fellowship at the University of Mississippi Medical Center in Jackson. Dr. Hansen completed a Fellowship in Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Dr. Hansen’s clinical interests include autologous and allogeneic hematopoietic stem cell transplantation for disease processes such as leukemia and multiple myeloma in addition to Chimeric Antigen Receptor Therapy (CAR-T) for plasma cell dyscrasias. Dr. Hansen’s research interests include identification of strategies for longer survival, relapse prevention based on minimal residual disease (MRD) and development of a multiple myeloma CAR-T database to advance research efforts for the prevention and cure of cancer. 


Education & Training

Fellowship:

  • Moffitt Cancer Center -

Medical School:

  • St. George's University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 20816
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Condition: Malignant Hematology
Intervention: Bortezomib (); CC-4047 (Pomalidomide); CC-5013 (Lenalidomide); Ixazomib (); Lenalidomide (Revlimid); PS-341 (Bortezomib); Pomalidomide (); Velcade (Bortezomib); carfilzomib (Kyprolis)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Apr.41(11):2087-2097. Pubmedid: 36623248. Pmcid: PMC10082273.
  • Oswald LB, Li X, Carvajal R, Hoogland AI, Gudenkauf LM, Hansen DK, Alsina M, Locke FL, Rodriguez Y, Irizarry-Arroyo N, Robinson EJ, Jim HSL, Gonzalez BD, Kirtane K. Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers (Basel). 2022 May.14(11). Pubmedid: 35681722. Pmcid: PMC9179384.
  • Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee CH, Mian H, Nathan S, Savani BN, Kumar SK, Qazilbash MH, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 Jul.6(13):3991-3995. Pubmedid: 35507742. Pmcid: PMC9278304.
  • Peres LC, Hansen DK, Maura F, Kazandjian D. The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S. Semin Oncol. 2022 Feb.49(1):3-10. Pubmedid: 35219512.
  • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
  • Masood A, Iqbal Q, Ehsan H, Davis JA, Hansen DK, Hashmi H. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature. Ann Hematol. 2022 Dec.101(12):2601-2610. Pubmedid: 36214853.
  • Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
  • Hansen DK, Dam M, Faramand RG. Toxicities associated with adoptive cellular therapies. Best Pract Res Clin Haematol. 2021 Sep.34(3):101287. Pubmedid: 34625233.
  • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
  • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
  • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.

Grants

Title: Racial and ethnic disparities among multiple myeloma patients treated with CAR-T therapy: Investigation of treatment response, immune-related adverse events, and patient reported outcomes
Sponsor: Moffitt Cancer Center
PI (Contact): Hansen, D., PI: Oswald, L., PI: Peres, L.
Title: PILOT STUDY TO DEVELOP A PREDICTIVE MODEL OF IMMUNE-RELATED ADVERSE EVENTS IN MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL IN THE STANDARD OF CARE SETTING
Sponsor: Bristol Myers Squibb Company
PI: Hansen, D., CO-PI: Peres, L.
Title: Real-world Clinical and Patient-reported Outcomes among Patients with Relapsed/refractory Multiple Myeloma Treated with Commercial CAR-T Therapy
Sponsor: Moffitt Cancer Center
PI (Contact): Hansen, D., PI: Oswald, L., PI: Peres, L.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

33 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments